Cargando…
Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the norm...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223535/ https://www.ncbi.nlm.nih.gov/pubmed/25401051 http://dx.doi.org/10.1007/s40139-014-0057-8 |
_version_ | 1782343211824447488 |
---|---|
author | Iwaisako, Keiko Taura, Kojiro Koyama, Yukinori Takemoto, Kenji Asagiri, Masataka |
author_facet | Iwaisako, Keiko Taura, Kojiro Koyama, Yukinori Takemoto, Kenji Asagiri, Masataka |
author_sort | Iwaisako, Keiko |
collection | PubMed |
description | Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the normal liver, are differentiated from heterogeneous cell populations in response to a liver injury of any etiology and produce the extracellular matrix. Hepatic stellate cells are considered the main source of myofibroblasts. However, the origin of hepatic myofibroblasts remains unresolved, and despite considerable research, only a limited success has been achieved by existing anti-fibrotic therapies. The question remains whether these limitations are caused by lack of attention to the critical targets, the myofibroblasts derived from cells of other mesenchymal origins. Therefore, identifying the origin of myofibroblasts may provide insight into the mechanisms underlying liver fibrosis, and may lead to the development of more effective therapies. This review will examine our current strategies for detecting hepatic myofibroblasts of different origins. |
format | Online Article Text |
id | pubmed-4223535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-42235352014-11-12 Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies Iwaisako, Keiko Taura, Kojiro Koyama, Yukinori Takemoto, Kenji Asagiri, Masataka Curr Pathobiol Rep Myofibroblast (Tatiana Kisseleva, Section Editor) Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the normal liver, are differentiated from heterogeneous cell populations in response to a liver injury of any etiology and produce the extracellular matrix. Hepatic stellate cells are considered the main source of myofibroblasts. However, the origin of hepatic myofibroblasts remains unresolved, and despite considerable research, only a limited success has been achieved by existing anti-fibrotic therapies. The question remains whether these limitations are caused by lack of attention to the critical targets, the myofibroblasts derived from cells of other mesenchymal origins. Therefore, identifying the origin of myofibroblasts may provide insight into the mechanisms underlying liver fibrosis, and may lead to the development of more effective therapies. This review will examine our current strategies for detecting hepatic myofibroblasts of different origins. Springer US 2014-09-14 2014 /pmc/articles/PMC4223535/ /pubmed/25401051 http://dx.doi.org/10.1007/s40139-014-0057-8 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Myofibroblast (Tatiana Kisseleva, Section Editor) Iwaisako, Keiko Taura, Kojiro Koyama, Yukinori Takemoto, Kenji Asagiri, Masataka Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
title | Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
title_full | Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
title_fullStr | Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
title_full_unstemmed | Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
title_short | Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies |
title_sort | strategies to detect hepatic myofibroblasts in liver cirrhosis of different etiologies |
topic | Myofibroblast (Tatiana Kisseleva, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223535/ https://www.ncbi.nlm.nih.gov/pubmed/25401051 http://dx.doi.org/10.1007/s40139-014-0057-8 |
work_keys_str_mv | AT iwaisakokeiko strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies AT taurakojiro strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies AT koyamayukinori strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies AT takemotokenji strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies AT asagirimasataka strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies |